PreTT is transforming cancer treatment with advanced pretargeted radioligand therapies that
surpass traditional methods. Our proprietary technology enhances radioimmunotherapy, using
monoclonal antibodies (mAbs) for precise targeting of cancer cells while sparing healthy tissue.
This innovation maximizes radiation’s therapeutic power, offering a powerful new tool in the
fight against cancer.